CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-07-24). The draft was written by AI, the existence of all 2 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 1628 · Search date 2026-07-24 · Methodology v0.6

Oral semaglutide 14 mg,
does it really help with Delayed cognitive and functional decline in early Alzheimer disease?

30-Second Summary
F
Evidence Grade F · 10 · Safety unknown
Biomarkers changed, but cognitive and functional decline did not slow
What the
research shows
Oral semaglutide is rated F for this indication. EVOKE and EVOKE+ were two separate large phase 3 trials of the same drug in the same early Alzheimer disease indication, totaling 3,808 participants. Both failed the week-104 CDR-SB primary endpoint, clinical secondary outcomes were concordantly null, and biomarker changes did not translate into clinical benefit.
What the
ads claim
Benefits in diabetes, obesity, or cardiovascular indications cannot be transferred to Alzheimer disease. This verdict is separate from verdicts 615, 1191, 1587, and 1593 in other indications.
*

Useful facts when choosing a product

  • Once-daily oral semaglutide was titrated from 3 mg to a maximum of 14 mg.
  • EVOKE and EVOKE+ followed 3,808 people with early symptomatic Alzheimer disease for 104 weeks.
  • Neither trial showed clinically slower progression on CDR-SB versus placebo.
  • Gastrointestinal adverse effects and loss of weight, lean mass, or muscle warrant attention in older patients.
Gap Measurement · Verdict 1628 · F 10
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

The two randomized double-blind phase 3 trials added oral semaglutide up to 14 mg or placebo to standard care for 104 weeks. Across 3,808 participants neither trial showed CDR-SB superiority, and confirmatory clinical secondary outcomes did not support efficacy.

02

Why this is classified as F (10)

Two large trials of the same drug in the same indication each failed, giving F with 10 points. Biomarker-only changes did not raise the grade.

Counterpoint. Efficacy in other metabolic or cardiovascular indications does not alter this Alzheimer verdict.

Rejudgment record. New verdict — Two separate large phase 3 trials of the same drug in the same early Alzheimer disease indication each failed the primary and concordant clinical secondary endpoints

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Delayed cognitive declineFRepeatedly null in two large trials in the same indication.
Delayed functional declineFCDR-SB and clinical secondary outcomes were null.
Delayed clinical progression of Alzheimer diseaseFBiomarker changes did not translate into clinical benefit.

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
EVOKE and EVOKE+ phase 3 trials, 2025 primary resultsTwo separate randomized double-blind placebo-controlled phase 3 trials3,808Novo NordiskWeek-104 CDR-SBBoth failed superiority; clinical secondary outcomes were also null.Repeated confirmatory failure in the same indication
Cummings J et al. 2025 design paperDesign report for both phase 3 trials1,953Novo NordiskCDR-SB and cognitive and functional secondary outcomesDocuments two separate confirmatory trials in the same indication.Design and sample verification
§

Receipt — 2 References

All 2 cited sources were verified for existence at the original page (as of 2026-07-24).

Cummings JL, Atri A, Feldman HH, et al. evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease. Alzheimers Res Ther. 2025;17(1):14. PMCID: PMC11708093. DOI: 10.1186/s13195-024-01666-7.
checked
Novo Nordisk. EVOKE phase 3 trials did not demonstrate a statistically significant reduction in Alzheimer's disease progression. Company announcement. November 24, 2025. PMID: none. DOI: none.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-24 · Corrections: none

Cite this verdict

Oral semaglutide 14 mg x delayed progression of early Alzheimer disease Evidence Grade F card
[Chamgap] Oral semaglutide 14 mg x delayed progression of early Alzheimer disease — Evidence Grade F·10. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/cognition/oral-semaglutide-14mg-early-alzheimers-cognitive-functional-decline/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.